Estrella Immunopharma, Inc. (ticker: ESLA) is an NASDAQ-listed clinical research company. DredgeCap's structured extraction of ESLA's SEC filings surfaces 4 active risk signals, including 2 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. ESLA reported no tagged revenue in revenue and -$13.06M for the period ending 2025-12-31, with operating cash flow of -$1.79M. Cash and equivalents stood at $1.38M (up 51% year-over-year). Total assets of $3.18M are exceeded by total liabilities of $13.54M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
ESLA Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Estrella Immunopharma, Inc. (ESLA) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.